

January 30, 2026

Q3FY26 Result Update

☒ Change in Estimates | ☒ Target | ☒ Reco

Change in Estimates

	Current		Previous	
	FY27E	FY28E	FY27E	FY28E
Rating	BUY		ACCUMULATE	
Target Price	929		860	
Sales (Rs. m)	65,574	82,075	64,044	83,162
% Chng.	2.4	(1.3)		
EBITDA (Rs. m)	6,240	7,909	5,774	7,515
% Chng.	8.1	5.2		
EPS (Rs.)	21.1	26.5	18.7	24.3
% Chng.	13.3	9.0		

Key Financials - Consolidated

Y/e Mar	FY25	FY26E	FY27E	FY28E
Sales (Rs. m)	37,867	46,693	65,574	82,075
EBITDA (Rs. m)	3,233	5,064	6,240	7,909
Margin (%)	8.5	10.8	9.5	9.6
PAT (Rs. m)	1,699	3,045	4,065	5,103
EPS (Rs.)	9.5	15.8	21.1	26.5
Gr. (%)	57.7	65.9	33.5	25.5
DPS (Rs.)	1.5	1.5	1.5	1.5
Yield (%)	0.2	0.2	0.2	0.2
RoE (%)	10.1	12.7	12.6	14.0
RoCE (%)	13.0	16.8	16.8	18.4
EV/Sales (x)	3.6	2.9	2.1	1.7
EV/EBITDA (x)	42.4	27.1	22.3	17.5
PE (x)	79.1	47.7	35.7	28.5
P/BV (x)	7.7	4.8	4.3	3.7

Key Data SYRM.BO | SYRMA IN

52-W High / Low	Rs.910 / Rs.355
Sensex / Nifty	82,270 / 25,321
Market Cap	Rs.146bn / \$ 1,583m
Shares Outstanding	193m
3M Avg. Daily Value	Rs.1399.62m

Shareholding Pattern (%)

Promoter's	42.98
Foreign	7.02
Domestic Institution	16.38
Public & Others	33.62
Promoter Pledge (Rs bn)	-

Stock Performance (%)

	1M	6M	12M
Absolute	4.5	(1.0)	40.8
Relative	7.5	(2.0)	31.4

Praveen Sahay

praveensahay@plindia.com | 91-22-66322369

Rahul Shah

rahulshah@plindia.com | 91-22-66322534

Strong orderbook & exports to drive growth

We upward revise our earnings estimates for FY27/FY28 by 13.3%/9.0% and upgrade rating to 'BUY' due to strong performance. Syрма SGS Technology (SYRMA) has reported robust earnings growth of ~108% YoY for Q3FY26. Growth was driven by a 350bps YoY expansion in EBITDA margin to 12.6%, attributed to a favorable segment mix (with consumer contribution reducing to 31% of revenue) and improved operating efficiency. Its orderbook stood at Rs64bn, driven by industrials and auto segments. SYRMA has maintained its revenue growth guidance of 30%, but upgraded its EBITDA margin guidance to 10%+ from 9% for FY26; revenue growth will be driven by auto and industrials segments. SYRMA expects exports to reach Rs11bn by FY26 (Rs8.4bn in 9MFY26), driven by the industrials and medtech segments and supported by the EU-India FTA. The management anticipates 25-30% growth in exports in FY27, backed by strong EU market exposure. The company expects to receive PLI benefit of Rs300-320mn in FY26. We estimate FY25-28E revenue/EBITDA/PAT CAGR of 29.4%/34.7%/43.7%. Upgrade to 'BUY' from 'Accumulate' with TP of Rs929 (earlier Rs860) valuing at 35x Mar'28 earnings.

Q3FY26 financial performance: Revenue grew by 45.4% YoY to Rs12.6bn (PLe: Rs10.7bn). Auto/Consumer/Healthcare/Industrials/IT & Railways grew by 43.7%/43.0%/47.4%/45.1%/65.0% YoY. EBITDA grew by ~100% YoY to Rs1.6bn (PLe: Rs1.0bn). EBITDA margin expanded by ~350bps to 12.6% (PLe: 9.7%). PBT grew by ~116% YoY to Rs1.4bn (PLe: Rs791mn). PAT grew by 108% YoY to Rs1.1bn (PLe: Rs562mn).

9MFY26 financial performance: Revenue grew by 17.2% YoY to Rs33.5bn. Auto/Healthcare/Industrials/IT & Railways grew by 30.5%/30.5%/29.4%/70.7% YoY, whereas the consumer segment declined by ~8.0% YoY as the company is focusing on high-margin segments. EBITDA grew by 85.2% YoY to Rs3.6bn. EBITDA margin expanded by ~400bps to 10.8%. PBT grew by 104.6% YoY to Rs3.0bn. PAT grew by 99.1% YoY to Rs2.2bn.

Q3FY26 Concall Highlights

- Guidance for FY26:** The management has maintained its guidance of 30% revenue growth in FY26, which will be driven by the industrials and automotive segments, while revising EBITDA margin guidance to 10%+ from 9%, and expects similar growth in FY27.
- The management expects exports to grow to Rs11bn (Rs8.4bn in 9MFY26), driven by the industrials and medtech segments, and supported by the EU-India FTA. We see the FTA as a long-term positive, considering the duty reductions on end equipment such as automobiles and the company's strong exposure to the EU market. The management expects exports to grow 25-30% in FY27.

- **Segmental highlights:** In Q3FY26, the consumer segment was driven by the telecom business, including set-top box (IDU/ODU) programs, along with continued traction in ODM-led consumer products such as water purification systems and limited RFID-based applications.
- Industrials' growth was broad-based, with smart meters contributing to ~Rs500mn, while the balance was supported by exports, power supplies, telecom-related applications, and other industrial programs.
- The management highlighted that the smart meter business is 'sticky' due to a long working capital cycle, and is being selective with customers to ensure sales translate into positive cash flow. For FY26, the company expects smart meter revenue of ~Rs2bn, with 20–30% growth next year.
- IT & railways revenue stood at Rs 825mn in Q3FY26, with railways contributing Rs170–180mn, while the balance was driven by IT-related programs.
- Healthcare contributed Rs1.bn (primarily to the US) and industrials contributed Rs1.8bn (largely to Europe) to exports revenue, with geographical distribution for the 9MFY26 being ~5% exports to the US and ~35% to Europe for healthcare, while ~90% to Europe for industrials.
- **Strong orderbook across segments:** The company's orderbook stood at Rs64bn in Q3FY26, with contributions from auto (31%), consumer (25%), and industrials (27%), while the balance came from other segments. Export orders accounted for 24–25% of the orderbook, driven by the industrials, medtech and healthcare segments.
- **Capex plans for PCB manufacturing:** SYRMA plans to expand PCB manufacturing in phases, with a capex of Rs3.6–4.0bn for Phase 1 (completion by Dec'26), creating 720,000sqm of multi-layer and 480,000sqm of single-layer PCB capacity.
- The capex will be funded through 50% debt and 50% equity, with 25% of the equity contribution provided by a partner, and the company expects a 50% subsidy from Andhra Pradesh government. Funding will be supported by a combination of operating cash flow, equity infusion, and debt, with the government subsidy acting as bridge financing over FY27–28.
- The facility is being built to accommodate 2 additional multi-layer lines, which may be commissioned earlier than planned due to strong customer interest. The broader PCB-related expansion, including CCL, HDI and flex projects, is dependent on government approvals, with total capex of Rs15bn expected to be spent by FY30.
- SYRMA stated that in its PCB business, bulk consumption largely comprises single- to sub-8-layer boards, accounting for 70–75% of total PCB demand, while higher layer PCBs (8–15 layers and HDI boards) represent a much smaller volume. The company intends to focus on the bulk market initially, though it may selectively target higher layer PCBs where demand exists.

- The company is engaging with industrials, automotive and consumer segments, targeting 15–17% EBITDA margin in line with industry norms, focusing initially on accessible opportunities while progressively building a pipeline for high-end PCBAs, including medtech and export markets.
- **Other highlights:** SYRMA expects Elcome to deliver Rs 2.8-3bn in revenue FY26, with potential growth of 10–15% next year, driven by its existing product offerings and defense applications, which have a longer gestation period and can lead to lumpy orders. Elcome is having an EBITDA margin of 20–25%, which the management expects to sustain in the coming years. However, revenue for Elcome will not be recorded fully in FY26 as it was acquired recently in Dec'25.
- The company expects PLI benefit of Rs300-320mn for FY26.

Exhibit 1: Q3FY26 result overview: Sales grows by 45.4% YoY, PAT up by 108.1% YoY

Y/e March (Rs mn)	Q3FY26	Q3FY25	YoY gr. (%)	Q3FY26E	% Var.	Q2FY26	QoQ gr. (%)	9MFY26	9MFY25	YoY gr. (%)
Net Sales	12,642	8,697	45.4	10,681	18.4	11,459	10.3	33,540	28,623	17.2
Expenditure										
Operating & Manufacturing Expenses	9,174	6,430	42.7	8,139	12.7	8,730	5.1	25,011	22,583	10.7
<i>% of Net Sales</i>	<i>72.6</i>	<i>73.9</i>		<i>76.2</i>		<i>76.2</i>		<i>74.6</i>	<i>78.9</i>	
Gross Profit	3,468	2,267	53.0	2,542	36.4	2,728	27.1	8,530	6,040	41.2
<i>Gross Margin (%)</i>	<i>27.4</i>	<i>26.1</i>	<i>1.37</i>	<i>23.8</i>	<i>3.64</i>	<i>23.8</i>		<i>25.4</i>	<i>21.1</i>	
Personnel Cost	556	465	19.7	513	8.5	515	8.1	1,575	1,378	14.3
<i>% of Net Sales</i>	<i>4.4</i>	<i>5.3</i>		<i>4.8</i>		<i>4.5</i>		<i>4.7</i>	<i>4.8</i>	
Other Expenses	1,318	1,006	31.0	993	32.7	1,061	24.2	3,343	2,711	23.3
<i>% of Net Sales</i>	<i>10.4</i>	<i>11.6</i>		<i>9.3</i>		<i>9.3</i>		<i>10.0</i>	<i>9.5</i>	
Total Expenditure	11,048	7,901	39.8	9,645	14.5	10,307	7.2	29,928	26,672	12.2
EBITDA	1,594	796	100.3	1,036	53.9	1,152	38.3	3,613	1,951	85.2
<i>Margin (%)</i>	<i>12.6</i>	<i>9.1</i>	<i>3.46</i>	<i>9.7</i>	<i>2.91</i>	<i>10.1</i>		<i>10.8</i>	<i>6.8</i>	<i>3.95</i>
Depreciation	203	202	0.3	218	-7.2	218	-7.2	627	543	15.4
EBIT	1,391	593	134.5	818	70.2	934	49.0	2,985	1,408	112.1
Other income	103	218	-52.7	100	3.0	87	17.7	351	471	(25.5)
Interest	77	154	-50.2	126	-39.2	126	-39.2	352	421	(16.2)
PBT	1,417	657	115.8	791	79.1	895	58.4	2,984	1,458	104.6
Total Taxes	280	105	166.3	199	40.8	232	21.1	684	307	122.8
<i>ETR (%)</i>	<i>19.8</i>	<i>16.0</i>		<i>25.2</i>		<i>25.9</i>		<i>22.9</i>	<i>21.1</i>	
Adj. PAT	1,137	551	106.2	562	102.3	663	71.4	2,200	1,109	98.3
Exceptional Items	(34)	(21)		-		-		(34)	87	
Reported PAT	1,103	530	108.1	562	96.3	663	66.3	2,166	1,088	99.1

Source: Company, PL

Exhibit 2: Segmental breakup – Auto/Industrials up by 43.7%/45.1% YoY

Y/e March (Rs mn)	Q3FY26	Q3FY25	YoY gr. (%)	Q2FY26	QoQ gr. (%)	9MFY26	9MFY25	YoY gr. (%)
Revenues								
Auto	2,990	2,081	43.7	2,710	10.3	7,915	6,067	30.5
Consumer	3,866	2,704	43.0	3,656	5.7	10,700	11,585	(7.6)
Healthcare	1,082	734	47.4	834	29.7	2,590	1,984	30.5
Industrials	3,879	2,674	45.1	2,649	46.4	9,401	7,265	29.4
IT and Railways	825	500	65.0	1,610	(48.8)	2,935	1,719	70.7
Total	12,642	8,693	45.4	11,459	10.3	33,541	28,620	17.2

Source: Company, PL

Financials

Income Statement (Rs m)

Y/e Mar	FY25	FY26E	FY27E	FY28E
Net Revenues	37,867	46,693	65,574	82,075
YoY gr. (%)	20.1	23.3	40.4	25.2
Cost of Goods Sold	29,315	34,769	49,484	61,937
Gross Profit	8,552	11,924	16,089	20,138
Margin (%)	22.6	25.5	24.5	24.5
Employee Cost	1,910	2,148	2,833	3,447
Other Expenses	3,409	4,711	7,016	8,782
EBITDA	3,233	5,064	6,240	7,909
YoY gr. (%)	59.9	56.6	23.2	26.7
Margin (%)	8.5	10.8	9.5	9.6
Depreciation and Amortization	751	831	927	1,143
EBIT	2,482	4,233	5,313	6,766
Margin (%)	6.6	9.1	8.1	8.2
Net Interest	585	428	305	389
Other Income	494	435	450	485
Profit Before Tax	2,371	4,207	5,459	6,863
Margin (%)	6.3	9.0	8.3	8.4
Total Tax	526	1,009	1,374	1,727
Effective tax rate (%)	22.2	24.0	25.2	25.2
Profit after tax	1,845	3,198	4,085	5,135
Minority interest	146	153	19	32
Share Profit from Associate	-	-	-	-
Adjusted PAT	1,699	3,045	4,065	5,103
YoY gr. (%)	58.3	79.2	33.5	25.5
Margin (%)	4.5	6.5	6.2	6.2
Extra Ord. Income / (Exp)	-	-	-	-
Reported PAT	1,699	3,045	4,065	5,103
YoY gr. (%)	58.3	79.2	33.5	25.5
Margin (%)	4.5	6.5	6.2	6.2
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	1,699	3,045	4,065	5,103
Equity Shares O/s (m)	178	192	192	192
EPS (Rs)	9.5	15.8	21.1	26.5

Source: Company Data, PL Research

Balance Sheet Abstract (Rs m)

Y/e Mar	FY25	FY26E	FY27E	FY28E
Non-Current Assets				
Gross Block	10,407	11,935	15,574	18,218
Tangibles	10,019	11,450	14,969	17,461
Intangibles	388	484	606	757
Acc: Dep / Amortization	2,185	3,016	3,942	5,085
Tangibles	1,989	2,673	3,490	4,497
Intangibles	195	343	452	589
Net fixed assets	8,222	8,919	11,632	13,133
Tangibles	8,030	8,778	11,478	12,965
Intangibles	192	141	153	168
Capital Work In Progress	656	665	676	639
Goodwill	3,221	3,221	3,221	3,221
Non-Current Investments	291	162	162	162
Net Deferred tax assets	(117)	(117)	(117)	(117)
Other Non-Current Assets	226	226	226	226
Current Assets				
Investments	514	514	514	514
Inventories	8,219	9,594	13,474	16,865
Trade receivables	14,775	18,805	25,511	31,931
Cash & Bank Balance	2,958	8,812	8,674	9,144
Other Current Assets	1,960	2,339	3,149	3,898
Total Assets	42,047	54,263	68,245	80,739
Equity				
Equity Share Capital	1,780	1,924	1,924	1,924
Other Equity	15,719	28,385	32,162	36,977
Total Network	17,500	30,309	34,086	38,900
Non-Current Liabilities				
Long Term borrowings	619	0	150	150
Provisions	152	171	226	275
Other non current liabilities	67	83	117	146
Current Liabilities				
ST Debt / Current of LT Debt	5,579	1,437	2,697	2,802
Trade payables	15,744	19,413	27,264	34,124
Other current liabilities	812	1,018	1,425	1,781
Total Equity & Liabilities	42,047	54,263	68,245	80,739

Source: Company Data, PL Research

Cash Flow (Rs m)

Y/e Mar	FY25	FY26E	FY27E	FY28E
PBT	2,371	4,241	5,459	6,863
Add. Depreciation	751	831	927	1,143
Add. Interest	585	428	305	389
Less Financial Other Income	494	435	450	485
Add. Other	(401)	(434)	(362)	(407)
Op. profit before WC changes	3,306	5,065	6,328	7,987
Net Changes-WC	(934)	(1,909)	(3,138)	(3,343)
Direct tax	(607)	(1,009)	(1,374)	(1,727)
Net cash from Op. activities	1,765	2,147	1,816	2,917
Capital expenditures	(2,452)	(1,537)	(3,651)	(2,608)
Interest / Dividend Income	169	435	450	485
Others	1,231	128	-	-
Net Cash from Inv. activities	(1,052)	(973)	(3,201)	(2,123)
Issue of share cap. / premium	(125)	143	-	-
Debt changes	330	(4,656)	1,840	352
Dividend paid	(266)	(267)	(289)	(289)
Interest paid	(513)	(428)	(305)	(389)
Others	(133)	-	-	-
Net cash from Fin. activities	(707)	(5,208)	1,247	(325)
Net change in cash	6	(4,034)	(137)	470
Free Cash Flow	(687)	610	(1,835)	309

Source: Company Data, PL Research

Key Financial Metrics

Y/e Mar	FY25	FY26E	FY27E	FY28E
Per Share(Rs)				
EPS	9.5	15.8	21.1	26.5
CEPS	13.8	20.1	26.0	32.5
BVPS	98.3	157.6	177.2	202.2
FCF	(3.9)	3.2	(9.5)	1.6
DPS	1.5	1.5	1.5	1.5
Return Ratio(%)				
RoCE	13.0	16.8	16.8	18.4
ROIC	10.0	17.5	15.8	17.0
RoE	10.1	12.7	12.6	14.0
Balance Sheet				
Net Debt : Equity (x)	0.2	(0.3)	(0.2)	(0.2)
Net Working Capital (Days)	70	70	65	65
Valuation(x)				
PER	79.1	47.7	35.7	28.5
P/B	7.7	4.8	4.3	3.7
P/CEPS	54.9	37.5	29.1	23.3
EV/EBITDA	42.4	27.1	22.3	17.5
EV/Sales	3.6	2.9	2.1	1.7
Dividend Yield (%)	0.2	0.2	0.2	0.2


Source: Company Data, PL Research

Quarterly Financials (Rs m)

Y/e Mar	Q4FY25	Q1FY26	Q2FY26	Q3FY26
Net Revenue	9,244	9,440	11,459	12,642
YoY gr. (%)	(18.5)	(18.6)	37.6	45.4
Raw Material Expenses	6,731	7,107	8,730	9,174
Gross Profit	2,512	2,333	2,728	3,468
Margin (%)	27.2	24.7	23.8	27.4
EBITDA	1,075	866	1,152	1,594
YoY gr. (%)	45.9	94.3	62.4	100.3
Margin (%)	11.6	9.2	10.1	12.6
Depreciation / Depletion	208	206	218	203
EBIT	867	660	934	1,391
Margin (%)	9.4	7.0	8.1	11.0
Net Interest	156	149	126	77
Other Income	223	160	87	103
Profit before Tax	934	671	895	1,417
Margin (%)	10.1	7.1	7.8	11.2
Total Tax	219	172	232	280
Effective tax rate (%)	23.5	25.7	25.9	19.8
Profit after Tax	715	499	663	1,137
Minority interest	60	2	23	75
Share Profit from Associates	-	-	-	-
Adjusted PAT	654	497	641	1,028
YoY gr. (%)	87.2	144.5	61.6	170.5
Margin (%)	7.1	5.3	5.6	8.1
Extra Ord. Income / (Exp)	-	-	-	-
Reported PAT	654	497	641	1,028
YoY gr. (%)	80.3	144.5	61.6	110.7
Margin (%)	7.1	5.3	5.6	8.1
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	654	497	641	1,028
Avg. Shares O/s (m)	178	178	178	192
EPS (Rs)	3.7	2.8	3.6	5.3

Source: Company Data, PL Research

Price Chart



Recommendation History

No.	Date	Rating	TP (Rs.)	Share Price (Rs.)
1	06-Jan-26	Accumulate	860	750
2	11-Nov-25	Accumulate	874	831
3	07-Oct-25	Accumulate	870	852
4	24-Jul-25	Hold	705	706
5	04-Jul-25	Hold	625	607
6	15-May-25	BUY	618	526
7	04-Apr-25	BUY	629	469

Analyst Coverage Universe

Sr. No.	Company Name	Rating	TP (Rs)	Share Price (Rs)
1	Amber Enterprises India	BUY	8,263	6,712
2	Astral Ltd.	BUY	1,736	1,487
3	Avalon Technologies	BUY	1,100	908
4	Bajaj Electricals	BUY	597	476
5	Cello World	BUY	732	533
6	Century Plyboard (I)	Hold	842	811
7	Cera Sanitaryware	BUY	7,372	5,177
8	Crompton Greaves Consumer Electricals	BUY	362	263
9	Cyient DLM	Accumulate	418	364
10	Finolex Industries	Accumulate	211	181
11	Greenpanel Industries	BUY	400	229
12	Havells India	Accumulate	1,634	1,447
13	Kajaria Ceramics	Hold	1,053	1,003
14	Kaynes Technology India	BUY	5,542	3,998
15	KEI Industries	BUY	5,573	3,853
16	LG Electronics India	BUY	1,920	1,456
17	Polycab India	BUY	9,744	7,122
18	Premier Energies	BUY	892	683
19	R R Kabel	BUY	1,788	1,537
20	Supreme Industries	BUY	4,566	3,349
21	Syrma SGS Technology	Accumulate	860	750
22	Vikram Solar	BUY	326	215
23	Voltas	Hold	1,442	1,349
24	Waaree Energies	BUY	3,600	2,599

PL's Recommendation Nomenclature (Absolute Performance)

Buy	: > 15%
Accumulate	: 5% to 15%
Hold	: +5% to -5%
Reduce	: -5% to -15%
Sell	: < -15%
Not Rated (NR)	: No specific call on the stock
Under Review (UR)	: Rating likely to change shortly

ANALYST CERTIFICATION

(Indian Clients)

We/I, Mr. Praveen Sahay- MBA Finance, Mr. Rahul Shah- MBA Finance Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

(US Clients)

The research analysts, with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is or will be directly related to the specific recommendation or views expressed in this research report.

DISCLAIMER

Indian Clients

Prabhudas Lilladher Pvt. Ltd, Mumbai, India (hereinafter referred to as "PL") is engaged in the business of Stock Broking, Portfolio Manager, Depository Participant and distribution for third party financial products. PL is a subsidiary of Prabhudas Lilladher Advisory Services Pvt Ltd. which has its various subsidiaries engaged in business of commodity broking, investment banking, financial services (margin funding) and distribution of third party financial/other products, details in respect of which are available at www.plindia.com.

This document has been prepared by the Research Division of PL and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of PL. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security.

The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy or completeness of the same. Neither PL nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein.

Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipient's particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor.

Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication.

PL may from time to time solicit or perform investment banking or other services for any company mentioned in this document.

PL is a registered with SEBI under the SEBI (Research Analysts) Regulation, 2014 and having registration number INH000000271.

PL submits that no material disciplinary action has been taken on us by any Regulatory Authority impacting Equity Research Analysis activities.

PL or its research analysts or its associates or his relatives do not have any financial interest in the subject company.

PL or its research analysts or its associates or his relatives do not have actual/beneficial ownership of one per cent or more securities of the subject company at the end of the month immediately preceding the date of publication of the research report.

PL or its research analysts or its associates or his relatives do not have any material conflict of interest at the time of publication of the research report.

PL or its associates might have received compensation from the subject company in the past twelve months.

PL or its associates might have managed or co-managed public offering of securities for the subject company in the past twelve months or mandated by the subject company for any other assignment in the past twelve months.

PL or its associates might have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months.

PL or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months

PL or its associates might have received any compensation or other benefits from the subject company or third party in connection with the research report.

PL encourages independence in research report preparation and strives to minimize conflict in preparation of research report. PL or its analysts did not receive any compensation or other benefits from the subject Company or third party in connection with the preparation of the research report. PL or its Research Analysts do not have any material conflict of interest at the time of publication of this report.

It is confirmed that Mr. Praveen Sahay- MBA Finance, Mr. Rahul Shah- MBA Finance Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

The Research analysts for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

The research analysts for this report has not served as an officer, director or employee of the subject company PL or its research analysts have not engaged in market making activity for the subject company

Our sales people, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

PL and its associates, their directors and employees may (a) from time to time, have a long or short position in, and buy or sell the securities of the subject company or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company or act as an advisor or lender/borrower to the subject company or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

US Clients

This research report is a product of Prabhudas Lilladher Pvt. Ltd., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Prabhudas Lilladher Pvt. Ltd. only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Prabhudas Lilladher Pvt. Ltd. has entered into an agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo").

Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

Prabhudas Lilladher Pvt. Ltd.

3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai-400 018, India | Tel: (91 22) 6632 2222 Fax: (91 22) 6632 2209

www.plindia.com